Evidence map›Paper›PMID 42570949›Full record

ArticleScientific reports2026

mRNA-based immunotherapy improves the efficacy of adoptively transferred TCR transgenic T cells in a murine solid tumour model.

Janna Krueger, Janne J Ruotsalainen, Johannes Lutz, Regina Heidenreich

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Janna KruegerCureVac SE, Friedrich-Miescher-Straße 15, 72076, Tübingen, Germany.ORCID 0009-0001-8477-3558
Janne J RuotsalainenCureVac SE, Friedrich-Miescher-Straße 15, 72076, Tübingen, Germany.ORCID 0000-0002-5312-5486
Johannes LutzCureVac SE, Friedrich-Miescher-Straße 15, 72076, Tübingen, Germany.ORCID 0000-0001-7452-0023
Regina HeidenreichCureVac SE, Friedrich-Miescher-Straße 15, 72076, Tübingen, Germany. regina.heidenreich@curevac.com.ORCID 0000-0002-8607-9412

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adoptive T cell therapy (ACT) has shown remarkable clinical success in treating haematological malignancies; however, its efficacy against solid tumours remains limited. This is largely due to poor persistence and functionality of transferred T cells, restricted tumour infiltration, and the presence of an immunosuppressive tumour microenvironment. Here, using the MC38-OVA murine tumour model, we tested whether combining Transgenic T cell receptor (TCR

Indexed as

CD8-Positive T-LymphocytesImmunotherapy, AdoptiveNeoplasmsReceptors, Antigen, T-CellRNA, MessengerAnimalsCell Line, TumorDisease Models, AnimalFemaleMiceMice, Inbred C57BLMice, TransgenicOvalbuminTumor MicroenvironmentOvalbuminReceptors, Antigen, T-CellRNA, MessengerAdoptive T cell therapy—ACTCancer immunotherapyCancer vaccineImmunotherapymRNATransgenic T cell receptor (TCR)

Identifiers

PMID42570949
PMCPMC13452821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.